Glenmark Pharmaceuticals Gains FDA Nod for Progesterone
ELMWOOD PARK, New Jersey, April 9, 2026 Glenmark Pharmaceuticals Limited has received final approval from the U.S. Food and...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ELMWOOD PARK, New Jersey, April 9, 2026 Glenmark Pharmaceuticals Limited has received final approval from the U.S. Food and...
ELMWOOD PARK, New Jersey, March 4, 2026 Glenmark Pharmaceuticals announced that the U.S. Food and Drug Administration has granted...
